Winners
Year |
City |
Winner |
2022 | Barcelona | PSMA and FDG PET as Predictive and Prognostic Biomarkers in Men with Metastatic, Castration-Resistant Prostate Cancer (mCRPC): an Analysis of the Randomised, Phase 2 Trial of [177Lu]Lu-PSMA-617 Versus Cabazitaxel (TheraP, ANZUP 1603) J. Buteau1, A. Martin2, L. Emmett3, A. Iravani4, S. Sandhu1, A. M. Joshua3, R. J. Francis5, A. Y. Zhang2, A. M. Scott6, S. Lee6, A. Azad1, M. McJannett7, M. R. Stockler8, S. Williams1, I. D. Davis9, M. S. Hofman1; 1Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, 2NHMRC Clinical Trials Centre, Sydney, AUSTRALIA, 3St-Vincent’s Hospital, Sydney, AUSTRALIA, 4Washington University, St. Louis, MO, UNITED STATES OF AMERICA, 5Sir Charles Gairdner Hospital, Perth, AUSTRALIA, 6Austin Health, Melbourne, AUSTRALIA, 7ANZUP, Sydney, AUSTRALIA, 8NHMRC CTC, Sydney, AUSTRALIA, 9Monash University and Eastern Health, Melbourne, AUSTRALIA. Next generation PET/CT imaging in meningioma using the novel SSTR-targeting peptide 18F-SiTATE – first clinical experiences [18F]AlF-NOTA-octreotide vs. [68Ga]Ga-DOTA-somatostatin analogue PET in neuroendocrine tumour patients: final results of a prospective multicentre trial |
2021 | Virtual | Longitudinal Evaluation Of The First Mutant Huntingtin PET Radioligand As A Marker For mHTT Lowering Therapies For Huntington’s Disease D. Bertoglio1, J. Verhaeghe1, S. De Lombaerde1,2, F. Zajicek1, T. Vasilkovska1, A. Miranda3, A. Gaertner4, B. Huscher4, A. Kakoulidou4, I. Cardaun4, A. Cornelius4, T. Schwagarus4, A. Van der Linden1, S. Stroobants1,2, Y. Wang5, M. Skinbjerg5, C. Dominguez5, V. Khetarpal5, L. Liu5, I. Munoz-Sanjuan5, J. Bard5, S. Staelens1; 1University of Antwerp, Wilrijk, BELGIUM, 2Antwerp University Hospital, Edegem, BELGIUM, 3University of Antwerp, Antwerpen, BELGIUM, 4Evotec SE, Hamburg, GERMANY, 5CHDI Management/CHDI Foundation, Los Angeles, CA, UNITED STATES OF AMERICA. A pilot study comparing 18F-FDG PET/CT and 68Ga-FAPI PET/CT for initial staging of early operable and locally advanced breast cancers 68Ga-FAPI-04 PET/CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-related interstitial lung disease |
2020 | Virtual | Ratiometric relationship between γH2AX imaging and Lutetium-177 is predictive of survival following radionuclide therapy in vivo E. O’Neill, G. M. Dias, B. Cornelissen; University of Oxford, Oxford, UNITED KINGDOM. [18F]AlF-NOTA-octreotide PET imaging: Pharmacokinetics, biodistribution, and head-to-head comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients [177Lu]Lu-PSMA-617 in low-volume metastatic hormone sensitive prostate cancer: a prospective pilot study |
2019 | Barcelona | Fluorine-18 Labeled FAPI-Tracers For PET Imaging T. Lindner1, A. Altmann1,2, F. L. Giesel1, C. Kratochwil1, C. Kleist1, S. Kraemer1, J. Debus3,4, W. Mier1, U. Haberkorn1,2,5; 1Nuclear Medicine, University Hospital Heidelberg, Heidelberg, GERMANY, 2Clinical Cooperation Unit Nuclear Medicine, German Cancer research Center (DKFZ), Heidelberg, GERMANY, 3Dept. of Radiation Oncology, University Hospital Heidelberg, Heidelberg, GERMANY, 4Clinical Cooperation Unit Radiation Oncology, German Cancer research Center (DKFZ), Heidelberg, GERMANY, 5Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, GERMANY. First Results of Targeted Alpha Peptide Receptor Radionuclide Therapy Using Ac-225 DOTATOC for Progressive Metastatic Neuroendocrine Neoplasms Tandem PSMA Radioligand Therapy Using Ac-225 and Lu-177 in Advanced Prostate Cancer: Safety and Efficacy Imaging DNA Damage in vivo following [177Lu]Lu-DOTATATE therapy in a model of pancreatic neuroendocrine cancer First extensive preclinical evaluation of PSMA-specific tracers for prostate cancer radioligand therapy |
2018 | Düsseldorf | Clinical outcome of 121 patients after PSMA-targeted radioguided surgery for early biochemical recurrent prostate cancer M. Kroenke1, T. Horn2, I. Rauscher1, S. Robu3, M. Schottelius3, H. Wester3, T. Maurer2, W. Weber1, M. Eiber1; 1Department of Nuclear medicine, Klinikum rechts der Isar, TUM, Munich, GERMANY, 2Department of Urology, Klinikum rechts der Isar, TUM, Munich, GERMANY, 3Chair of Pharmaceutical Radiochemistry, Department of Chemistry, TUM, Munich, GERMANY. A Complete Response following A Single Treatment with 225Ac-RPS-074 in LNCaP Xenografts First evidence for a dose-response relationship in hepatic holmium-166 radioembolization Development Of Stroma-targeted Theranostics Based On Inhibitors Of Fibroblast Activating Protein Novel targeted radionuclide therapy approach enhances response to immune checkpoint blockade in murine melanoma |
2017 | Vienna | Dual-labeled PSMA-11 for PET/CT imaging and precise fluorescence guided intraoperative identification of prostate cancer A. Baranski1, M. Schäfer1, U. Bauder-Wüst1, M. Roscher1, J. Schmidt1, E. Stenau1, T. Simpfendörfer2, L. Maier-Hein1, B. Hadaschik3, U. Haberkorn2, K. Kopka1, M. Eder4,1,5; 1German Cancer Research Center, Heidelberg, GERMANY, 2University Hospital, Heidelberg, GERMANY, 3University Hospital, Essen, GERMANY, 4University Hospital, Freiburg, GERMANY, 5German Cancer Consortium, Heidelberg, GERMANY. First experience using LMI1195 in patients with the suspicion of pheochromocytoma or paraganglioma TSPO-PET for high-grade glioma imaging using the novel ligand [18F]GE-180 – first in human results in the course of radiotherapy Monitoring tumor PD-L1 expression with microSPECT/CT during radiotherapy Radiocobalt-labeled anti-HER1 affibody molecule DOTA-ZEGFR:2377 for imaging of low HER1 expression in prostate cancer pre-clinical model |
2016 | Barcelona | 68Ga-PSMA PET/CT for early restaging prostate cancer. Preliminary results of a prospective trial in patients with biochemical failure after radical therapy and PSA levels < 2 ng/mL F. Ceci, P. Castellucci, T. Graziani, C. Fonti, F. Lodi, S. Boschi, S. Fanti; Service of Nuclear Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, ITALY. SPECT/CT imaging of the PD-1/PD-L1 immune checkpoint pathway in syngeneic murine tumor models Feasibility of in vivo imaging of VEGFR2 expression using high affinity antagonistic biparatopic affibody construct ZVEGFR2-Bp2 Prognostic significance of molecular and imaging biomarkers in primary brain tumors Value of F-DOPA PET in the long term follow up of radionecrotic brain metastases after radiosurgery: comparison with MRIF. Cicone1, L. Carideo1, C. Scaringi2, A. Romano3, A. Bozzao3, G. Minniti2, F. Scopinaro1; 1Unit of Nuclear Medicine, Sant’Andrea Hospital, “Sapienza” University of Rome, Rome, ITALY, 2Unit of Radiation Oncology, Sant’Andrea Hospital, “Sapienza” University of Rome, Rome, ITALY, 3Unit of Neuroradiology, Sant’Andrea Hospital, “Sapienza” University or Rome, Rome, ITALY. |
2015 | Hamburg | A phage display derived stabilised bicyclic peptide targeting MMP-14 shows high imaging contrast in small animal PET imaging A. M. Eder, S. Pavan, U. Bauder-Wüst, K. van Rietschoten, L. Baldassarre, U. Schierbaum, O. Seibert, K. Leotta, S. Campbell, H. Harrison, C. Stace, E. Walker, U. Haberkor, K. Kopka, D. P. Teufel; Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany Tc-99m-CXCL8 SPECT to image disease activity in inflammatory bowel disease Blunted striatal dopamine release in cannabis dependence Synergistically Enhanced Tumor Uptake via Dual-Targeting of CD105 and EGFR Using a “Click” Heterodimer Metastatic control probability in patients with prostate cancer metastatic to bone treated 186Re-HEDP |
2014 | Gothenburg | Quantitative analyses at Baseline and Interim PET evaluation for response assessment and outcome definition in patients with Malignant Pleural Mesothelioma (MPM) Egesta Lopci; Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), HUMANITAS (Rozzano), Milano, Italy A comparison of EGFR-targeted and non-targeted 177Lu-labeled gold nanoparticles (AuNPs) for localized radiation treatment of breast cancer xenografts in athymic mice Validation and applications for SNAP-tag imaging of bacterial infection. Non-FDG-avid areas inside a tumour mass in Paediatric Hodgkin Lymphoma (PHL) patients – A new risk factor? The QUEST Study: Correlating metabolic response with 90Y PET dosimetry for the treatment of metastatic liver cancer with radioembolisation |
2013 | Lyon | Development and pre-clinical evaluation of a new glucose-dependent insulinotropic polypeptide (GIP) based radioligand for PET imaging of a broad spectrum of neuroendocrine tumors Eleni Gourni; University Hospital, Department of Nuclear Medicine, Freiburg, GERMANY Synergistic anti-cancer response to chemotherapy and 177Lu-labelled APOMAB® radio immunotherapy in a preclinical model of lung cancer Tc99m labelled S-HYNIC Certolizumab Pegol for selecting patients for anti-TNFα treatment: a biodistribution and dosimetric study PET-guided radiotherapy planning in prostate cancer patients Evaluation of primary tumour and regional lymph node metastases with FDG PET/CT in breast cancer patients: prone versus supine position |
Year |
City |
Winner |
2022 | Barcelona | Best Oral Presentation Technologists Using a novel long-axial field-of-view (LAFOV) PET/CT system for dual tracer scanning with [68Ga]Ga-PSMA-11 and [18F]FDG PET/CT for PSMA-therapy assessment R. Schepers, K. Zeimpekis, M. Viscione, A. Rominger, A. Afshar-Oromieh, I. Alberts; Inselspital, Bern, SWITZERLAND. Second Best Oral Presentation Technologists A Tale of Serendipity from Misadministration M. Butfield, M. Vyas1,2, A. M. Henderson, A. Rowlings, J. Fagan, R. Joseph; 1Unitec Institute of Technology, Auckland, NEW ZEALAND, 2Mercy Radiology, Auckland, NEW ZEALAND. Third Best Oral Presentation Technologists Development of a Framework for Radiographer Online Clinical Education (FORCE): the specific strand of Nuclear Medicine within this European Project P. Costa1, J. Atutornu2, P. Bezzina3, N. Dalen4, J. Huhtanen5, M. Jaronen6, T. Saila6, B. Kraus7, L. Rainford8, K. Matthews8; 1Nuclear Medicine Department, School of Health – Polytechnic Institute of Porto (ESS|P.Porto), Porto, PORTUGAL, 2School of Health and Sports Sciences – University of Suffolk, Suffolk, UNITED KINGDOM, 3Faculty of Health Sciences – University of Malta, Msida, MALTA, 4Department of Health and Functioning – Western Norway University of Applied Sciences, Bergen, NORWAY, 5Health and Well-being, Rehabilitation, Oral Health Care and Diagnostic Services – Turku University of Applied Sciences, Turku, FINLAND, 6Social Services and Health Care – Tampere University of Applied Sciences, Tampere, FINLAND, 7University of Applied Sciences FH Campus Wien, Wien, AUSTRIA, 8School of Medicine – University College Dublin, Dublin, IRELAND. Best e-Poster Presentation Technologists Value of continuous blood pressure monitoring in the evaluation of maximal hyperemia during myocardial perfusion imaging with Rubidium-82 PET/CT A. Tegelaar – Kuiper1, S. S. Koenders1,2, J. A. van Dalen3, P. L. Jager1, J. D. van Dijk1; 1Department of Nuclear Medicine, Isala Hospital, Zwolle, NETHERLANDS, 2Technical Medical Centre, University of Twente, Enschede, NETHERLANDS, 3Department of Medical Physics, Isala Hospital, Zwolle, NETHERLANDS. |
2021 | Virtual | Best Oral Presentation Technologists Multiple-Time-Point 2-[18F]FDG PET/CT: Adrenal Glands Normal Metabolic Pattern Characterization I. Rodrigues1, A. Martins1, S. Carmona2, M. J. Vieira2, L. Oliveira1; 1Grupo Joaquim Chaves Saúde – Lisbon, Portugal/ Portuguese Red Cross Health School – Lisbon, Portugal, Lisbon, PORTUGAL, 2Grupo Joaquim Chaves Saúde – Lisbon, Portugal, Lisbon, PORTUGAL. Second Best Oral Presentation Technologists Comparative study of Dopamine transporter Imaging between a conventional camera and an innovative 3D-ring hybrid gamma-camera: technologist’s point of view J. Dessoubrais, P. Oudot, F. Clouse, M. Bailly; Regional Hospital Center of Orleans, Orléans, FRANCE. Third Best Oral Presentation Technologists Learning from our mistakes: a teaching tool to improve the quality of Nuclear Medicine Technologist’s practices E. A. Lemos Pereira, A. Garcia, A. Malaia, M. Fateixa; NuclearMed – Hospital Particular Almada, Almada, PORTUGAL. Best e-Poster Presentation Technologists PET/CT reconstruction study using 2 mm voxel size for improved image quality S. Rep1,2, P. Tomse1, L. Jensterle1, K. Zaletel1,3, L. Lezaic1,3; 1Department for Nuclear medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, 2Faculty of health sciences, Medical imaging and radiotherapy department, Ljubljana, SLOVENIA, 3Faculty of medicine, Ljubljana, SLOVENIA. |
2020 | Virtual | Best Oral Presentation Technologists Evaluation of data-driven gating for 68Ga-DOTATOC PET-CT in patients with neuroendocrine tumors J. Sigfridsson1, H. Romelin1, E. Lindström2,3, S. Kvernby2,3, I. Velikyan1,3, A. Sundin1,3, M. Lubberink1,3; 1PET Centre, Uppsala University Hospital, Uppsala, SWEDEN, 2Medical Physics, Uppsala University Hospital, Uppsala, SWEDEN, 3Radiology & Nuclear Medicine, Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN. Second Best Oral Presentation Technologists Dose reduction in FDG-PET by reconstruction optimization using resolution modelling A. Tegelaar-Kuiper1, S. Koenders1,2, D. Koopman1, P. G. Sanches3, B. N. Vendel1, H. Arkies1, J. A. van Dalen4; 1Department of Nuclear Medicine, Isala Hospital, Zwolle, NETHERLANDS, 2Technical Medical Centre, University of Twente, Enschede, NETHERLANDS, 3Health Systems, Philips Benelux, Eindhoven, NETHERLANDS, 4Department of Medical Physics, Isala Hospital, Zwolle, NETHERLANDS. Third Best Oral Presentation Technologists Ventilation scintigraphy: is it really safe now with COVID-19 pandemic? S. Mendes, I. Ferreira, J. Isidoro, G. Costa, P. Soeiro, J. P. Lima; Hospitais da Universidade de Coimbra, Coimbra, PORTUGAL. Best e-Poster Presentation Technologists Is there a role for 99mTc-PSMA in times of 18F-PSMA? T. Oliveira, B. Beier, J. Sailer, P. Peloscheck, M. Hoffmann; Radiology Center, Vienna, AUSTRIA. |
2019 | Barcelona | Best Oral Presentation Technologists Further Reduction Of [18F]-fdg Activity Applied In Clinical Routine For State-of-the-art 3d Tof Pet/ct Systems: Is It Feasible? J. Pilz, L. Hehenwarter, J. Holzmannhofer, G. Schweighofer-Zwink, C. Pirich; Second Best Oral Presentation Technologists Amyloid Positron Emission Tomography (PET) scanning: Process and pathway pitfalls and review L. Alves, B. Williams, D. Vilic, Z. Win Third Best Oral Presentation Technologists Review of protocol change for SLN injections in patients with breast cancer P. J. Campbell, H. Sharman, C. Caro Best e-Poster Presentation Technologists Influence of intravenous diuretics on the detectability of local prostate cancer recurrence in 68Ga-PSMA-11 PET/CT L. Dijkstra, I. Alberts, G. Prenosil, A. Rominger, A. Afshar-Oromieh; Second Best e-Poster Presentation Technologists Glomerular filtration rate: Comparison of two tracers L. Janus, T. Andersen, K. Thilsing-Hansen, D. Roholdt, C. Led, P. Andersen, H. Thomsen, O. Gerke, P. Høilund-Carlsen, J. Simonsen; Third Best e-Poster Presentation Technologists Lymphoscintigraphy and sentinel node localization in gynaecological cancers into practice: a UK single-centre protocol L. Pereira, K. Brooks, T. Barnden, O. Devaja, A. Corrigan |
2018 | Düsseldorf | Best Oral Presentation Semi-quantitative criteria for the diagnosis of the myocarditis using 99mTc-Pyrophosphate SPECT/CT J. Ilyushenkova, S. Sazonova, K. Zavadovsky 2nd Nominee for Best Oral Presentation Usefulness of SPECT for the semiquantitative assessment of regional 123I MIBG myocardial uptake in heart failure: comparison between iterative reconstruction (OSEM) versus filtered back projection A. Ruzza, I. Andreoli, G. Romagna, P. Basile, L. Filippi, O. Bagni 3rd Nominee for Best Oral Presentation Comparison of Gastric Emptying Results Using 60min, 90min and 120min Protocol – A Retrospective Study D. Teixeira Maçarico, C. Laurins, A. Nicol Best e-Poster Award 99mTc-MAA SPECT/CT-based dosimetry in SIRT: Why personalized dosimetry matters – A retrospective study L. Esteves, B. Collette, E. El Darazi, G. Verset, V. Lucidi, S. Goldman, R. Moreno-Reyes 2nd Nominee for Best e-Poster Presentation Standardised Uptake Value & Hounsfield Unit in lumber spine & head of the femur for Alkaptonuria measured from 18F-NaF PET/CT bone scan E. H. M. A. Alawadhi, S. Vinjamuri, J. Gallagher, R. Lakshminarayan 3rd Nominee for Best e-Poster Presentation Incidence of asymptomatic nephroptosis detected by 99mTc-MAG3 renogram S. Mendes, R. Silva, G. Costa, P. Soeiro, C. Barbosa, J. Rodrigues, I. Ferreira, J. P. Lima |
2017 | Vienna | Best Oral Presentation – CET Award 18F-FDG PET/CT in pediatric lymphoma patients: the role of technologist M.Ciaccio, C. Nava, D. Bonacina, M. Maurizio, A. Perri, A. Renaioli, S. Morzenti, L. Guerra, C. Crivellaro 2nd Nominee for Best Oral Presentation Improving alignment between 18F-FDG PET and CT scans by controling breathing movements during the CT-scan K. Lehnskov, C. P. Jønsson, L. B. Katz, D. A. Riisberg 3rd Nominee for Best Oral Presentation A review of thyroid blockade strategies used in paediatric I123MIBG scintigraphy, and an evaluation of their relative effectiveness B. Thurlow, T. Melhuish, P. Leanne, E. Morris, S. Johns, M. Guy, S. King, L. Biassoni Best Poster Award Residual Activity Correction Successfully Adjusts Myocardial Blood Flow Measurements in Time-efficient 13N-ammonia Myocardial Perfusion PET/CT P. A. Doodeman, S. V. Lazarenko, F. M. van der Zant, M. Wondergem, R. J. J. Knol 2nd Nominee for Best Poster Presentation Comparison of MPI SPECT/CT scans acquired with LEHR collimator and reduced time IQ SPECT system S. Ferreira, P. Begley, M. Jessop, A. Aldous, N. Eftychiou, N. Singh, S. Dizdarevic, E. Sousa 3rd Nominee for Best Poster Presentation A cost effective protocol for increasing patient throughout using a combination of half time imaging with 99mTc Tetrofosmin and Regadenoson in Stress Myocardial Perfusion Imaging P. J. Turner, T. Watts, F. Whittingham |
2016 | Barcelona | Best Oral Presentation – META Award The diagnostic quality of 18-F-FDG PET images from the PET/MR in comparison with the PET/CT E. Voets, M. G. W. Visser, F. M. Mottaghy, S. Vöö 2nd Nominee for Best Oral Presentation First clinical experience with SUVmax cuantification by a dedecated breast PET compared to PET-CT. R. SANCHEZ JURADO, J. FERRER REBOLLEDA, M. COZAR SANTIAGO, J. AGUILAR BARRIOS, R. BRISA VAZQUEZ, A. VICEDO GONZALEZ 3rd Nominee for Best Oral Presentation A European phantom study to cross-calibrate myocardial 123I-mIBG scintigraphy E. Poel, D. O. Verschure, K. Nakajima, K. Okuda, B. L. F. van Eck-Smit, G. A. Somsen, H. J. Verberne Best Poster Award Preoperative localisation of hyperfunctioning parathyroid glands; A preliminary comparison between99mTc-sestaMIBI / 123I scintigraphy and 18F-fluorocholine PET/CT E. Jansen, M. Wondergem, F. M. Van der Zant, R. J. J. Knol 2nd Nominee for Best Poster Presentation Calculating the Effective Dose from the CT Component of a SPECT/CT Study A. M. Cheetham, G. Havariyoun, E. Kalogianni, D. Ruiz, L. Devlin, N. Gulliver, A. Eccles, N. Mulholland, G. Vivian 3rd Nominee for Best Poster Presentation Upgrading Siemens software from Caredose mAs to both Caredose mAs and kV: Impact on patient radiation doses B. Dall, C. Schulze, C. S. Knudsen, A. E. Ljunggren |
2015 | Hamburg | Best Oral Presentation – META Award Radiation Dose to the Eye Lens: Does Positioning Really Matter? C. Baun, K. Falch, K. D. Nielsen, S. Shanmuganathan, O. Gerke, P. Hoeilund-Carlsen 2nd Nominee for Best Oral Presentation Adaptation of 13N-NH3 and 18F-FDG Imaging Protocols for sarcoidosis for new scanner technology C. Abreu, J. O’Doherty, S. Barrington, S. Pereira, L. Alves, J. John, P. Schleyer 3rd Nominee for Best Oral Presentation Radionuclide therapy of metastatic melanoma with benzamide derivate I-131-BA100 after patient stratification with F-18-DOPA F. O. Spohn, K. Kunze, F. Giesel, W. Mier, U. Haberkorn, C. Kratochwil Best Poster Award Evaluation of the quality of neuroimaging features as Alzheimer’s Disease biomarkers F. Lucena, T. F. Vaz, J. Pé-Leve, A. S. Ribeiro, L. Lacerda, N. Silva, D. Nutt, J. McGonigle, H. A. Ferreira 2nd Nominee for Best Poster Presentation Comparative retrospective study of peptide receptor radionuclide therapy (PRRT) with Y-90-DOTATOC and Y-90-DOTATATE in neuroendocrine tumours (NET) M. Marx, H. Plagge, C. Winkler, Y. Zhao, U. Lützen, M. Zuhayra 3rd Nominee for Best Poster Presentation Biodistribution Assessment of Sodium Pamidronate and Methylene Diphosphonate for Rats Bone Scintigraphy Images T. S. C. Camozzato, A. Z. P. De Souza, M. Tizon, S. J. Garcia, V. F. Dutra1, T. G. Costa |
2014 | Gothenburg | Best Oral Presentation – META Award Role of Advanced Practitioner in the clinical setting of a multi-disciplinary clinic for alpha emitting 223Radium-dichloride therapy for bone metastases in castration-resistant prostate cancer M. Jessop, A. Staker, K. Day, M. Aplin, N. Ryan, H. Cripps, A. Hosur, N. Singh, A. Robinson, S. Dizdarevic 2nd Nominee for Best Oral Presentation Is it possible to use Teflon cannulae for Radionuclide Equilibrium Angiography? M. Casanova Martins, C. Humphreys, A. Queiroz, C. Gascoigne, P. Ali 3rd Nominee for Best Oral Presentation Quantitative assessment of 18-FDG PET/CT and dbPET: Relationship with Breast Cancer prognostic factors R. Sanchez Jurado, M. Devis Saiz, A. Vicedo Gonzalez, J. Ferrer Rebolleda, J. Pamos Navas Best Poster Award Research Practice development in nuclear medicine technologists P. Chilra, S. Gnesin,G.Allenbach, J. Prior, C. Marques, C. Masias-Valdés, F. Descombes, L. Vieira, J. A. P. Jorge 2nd Nominee for Best Poster Presentation Comparison of Imaging Angle and Analysis Software on the Measurement of Left ventricular Ejection Fraction W-C. Way, C.Huang, J. Lin, S.Wang 3rd Nominee for Best Poster Presentation Interobserver and intraobserver variation of phase analysis results in ECG-gated myocardial perfusion SPECT related to repeated reconstructions M. Hakala, T. Koivumaki, M. Hakulinen, M. Kokkonen, A. Leinonen, T. Laitinen |
2013 | Lyon | Best Oral Presentation How low can you go: Dose-reduction in Low-Dose CT-scans for attenuation correction in myocardial perfusion imaging N. de Wit, B.J. Vermolen, P.J.G. Peeters, A.M. Scholtens, J.C.M. Buijs, H.W.A.M. de Jong 2nd Nominee for Best Oral Presentation PET/CT imaging of head-neck patients: Comparison of a one-step protocol and a two-step protocol C. S. Knudsen, A. Ljunggren, T. Beyer, F. Andersen, T. L. Klausen, K. Cappelen, A. K. Berthelsen, S. Holm, A. Loft 3rd Nominee for Best Oral Presentation Simultaneous PET/MR in breast cancer-first results C. Meisinger, I. Dregely, S. Schachoff, M. Schwaiger Best Poster Award Optimal number of iterations and attenuation correction method for the quantification of liver radioactivity on 99mTc-GSA SPECT/CT imaging Y. Nakamura, S. Tomiguchi, N. Katsuda, M. Hashida 2nd Nominee for Best Poster Presentation Evaluation of the basic characteristics of the cardiac focusing-collimators A. Niwa, S. Abe, T. Odagawa, N. Fujita, H. Kono, T. Kumazawa, Y. Fujita, K. Kato 3rd Nominee for Best Poster Presentation Causes and Actions in Relation to Defaulting Patients T. Godskesen |
Year |
City |
Winner |
2022 | Barcelona | EJNMMI Most Cited Paper Award Prediction of outcome using pretreatment 18F-FDG PET/CT and MRI radiomics in locally advanced cervical cancer treated with chemoradiotherapy. François Lucia, Dimitris Visvikis, Marie-Charlotte Desseroit, Omar Miranda, Jean-Pierre Malhaire, Philippe Robin, Olivier Pradier, Mathieu Hatt & Ulrike Schick, Eur J Nucl Med Mol Imaging 45,768–786 (2018). doi: 10.1007/s00259-017-3898-7 EJNMMI Best Paper Award EJNMMI Best Paper Award EJNMMI Best Paper Award EJNMMI Research Best Paper Award EJNMMI Physics Best Paper Award EJNMMI Radiopharmacy and Chemistry Best Paper Award European Journal of Hybrid Imaging Best Paper Award |
2021 | Virtual | EJNMMI Most Cited Paper Award Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients Ali Afshar-Oromieh, Tim Holland-Letz, Frederik L. Giesel, Clemens Kratochwil, Walter Mier, Sabine Haufe, Nils Debus, Matthias Eder, Michael Eisenhut, Martin Schäfer, Oliver Neels, Markus Hohenfellner, Klaus Kopka, Hans-Ulrich Kauczor, Jürgen Debus & Uwe Haberkorn, Eur J Nucl Med Mol Imaging 44, 1258–1268 (2017). doi: 10.1007/s00259-017-3711-7 EJNMMI Best Paper Award EJNMMI Best Paper Award EJNMMI Best Paper Award EJNMMI Research Best Paper Award EJNMMI Physics Best Paper Award EJNMMI Radiopharmacy and Chemistry Best Paper Award European Journal of Hybrid Imaging Best Paper Award |
2020 | Virtual | EJNMMI Most Cited Paper Award Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer Thomas Pyka, Shozo Okamoto, Marielena Dahlbender, Robert Tauber, Margitta Retz, Matthias Heck, Nagara Tamaki, Markus Schwaiger, Tobias Maurer & Matthias Eiber, Eur J Nucl Med Mol Imaging43,2114–2121 (2016). doi: 10.1007/s00259-016-3435-0 EJNMMI Best Paper Award EJNMMI Best Paper Award EJNMMI Best Paper Award EJNMMI Research Best Paper Award EJNMMI Physics Best Paper Award EJNMMI Radiopharmacy and Chemistry Best Paper Award European Journal of Hybrid Imaging Best Paper Award |
2019 | Barcelona | EJNMMI Most Cited Paper Award The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer Ali Afshar-Oromieh, Eleni Avtzi, Frederik L. Giesel, Tim Holland-Letz, Heinz G. Linhart, Matthias Eder, Michael Eisenhut, Silvan Boxler, Boris A. Hadaschik, Clemens Kratochwil, Wilko Weichert, Klaus Kopka, Jürgen Debus & Uwe Haberkorn, Eur J Nucl Med Mol Imaging (2015) 42: 197. doi:10.1007/s00259-014-2949-6 EJNMMI Best Paper Award EJNMMI Best Paper Award EJNMMI Best Paper Award EJNMMI Research Best Paper Award EJNMMI Physics Best Paper Award EJNMMI Radiopharmacy and Chemistry Best Paper Award European Journal of Hybrid Imaging Best Paper Award |
2018 | Düsseldorf | Most Cited Paper – EJNMMI Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience, Eur J Nucl Med Mol Imaging (2014) 41: 887. DOI 10.1007/s00259-013-2660-z, Author Block: Afshar-Oromieh, U. Haberkorn, H. P. Schlemmer, et al. Best Paper – EJNMMI Best Paper – EJNMMI Best Paper – EJNMMI Best Paper – EJNMMI Physics Best Paper – EJNMMI Research Best Paper – EJNMMI Radiopharmacy and Chemistry Best Paper – European Journal of Hybrid Imaging |
2017 | Vienna | Most Cited Paper – EJNMMI PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions, Eur J Nucl Med Mol Imaging (2013) 40: 486. doi: 10.1007/s00259-012-2298-2, Author Block: Afshar-Oromieh, A., Malcher, A., Eder, M. et al. Best Paper – EJNMMI Best Paper – EJNMMI Best Paper – EJNMMI Best Paper – EJNMMI Physics Best Paper – EJNMMI Research Best Paper – EJNMMI Radiopharmacy and Chemistry |
2016 | Barcelona | Most Cited Paper – EJNMMI Prognostic value of metabolic tumor burden on F-18-FDG PET in nonsurgical patients with non-small cell lung cancer, Eur J Nucl Med Mol Imaging (2012) 39: 27. doi:10.1007/s00259-011-1934-6, Author Block: Liao, S., Penney, B.C., Wroblewski, K. et al. Best Paper – EJNMMI Best Paper – EJNMMI Best Paper – EJNMMI Most Downloaded Paper – EJNMMI Physics Most Cited Paper – EJNMMI Research |
2015 | Hamburg | EJNMMI Most Cited Paper Automatic, three-segment, MR-based attenuation correction for whole-body PET/MR data, Eur J Nucl Med Mol Imaging (2011) 38:138–152 DOI 10.1007/s00259-010-1603-1, Author Block: V. Schulz, I. Torres-Espallardo, S. Renisch, Z. Hu, N. Ojha et al. EJNMMI Best Paper EJNMMI Best Paper EJNMMI Best Paper |
2014 | Gothenburg | EJNMMI Best Technical Paper Comparison of lesion detection and quantitation of tracer uptake between PET from a simultaneously acquiring whole-body PET/MR hybrid scanner and PET from PET/CT, January 2013, Volume 40, Issue 1, pp 12-21, Dr. Carl von Gall EJNMMI Best Basic Science Paper EJNMMI Best Clinical Paper EJNMMI Most Cited Paper
|
Year |
City |
Winner |
2022 | Barcelona | David Kersting (Essen, Germany) |